| An immune atlas of clear cell renal cell carcinoma S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ... Cell 169 (4), 736-749. e18, 2017 | 977 | 2017 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 831 | 2021 |
| Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide AJ Kettle, CA GEDYE, CC WINTERBOURN Biochemical Journal 321 (2), 503-508, 1997 | 283 | 1997 |
| Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells JM Stewart, PA Shaw, C Gedye, MQ Bernardini, BG Neel, LE Ailles Proceedings of the National Academy of Sciences 108 (16), 6468-6473, 2011 | 255 | 2011 |
| The regulatory T cell–associated transcription factor FoxP3 is expressed by tumor cells LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ... Cancer research 68 (8), 3001-3009, 2008 | 248 | 2008 |
| Inhibition of myeloperoxidase by benzoic acid hydrazides AJ Kettle, CA Gedye, MB Hampton, CC Winterbourn Biochemical Journal 308 (2), 559-563, 1995 | 209 | 1995 |
| Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response … L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ... Clinical genitourinary cancer 17 (1), 15-22, 2019 | 178 | 2019 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 170 | 2022 |
| Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial P Grimison, A Mersiades, A Kirby, N Lintzeris, R Morton, P Haber, I Olver, ... Annals of Oncology 31 (11), 1553-1560, 2020 | 151 | 2020 |
| Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the … CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ... European urology 76 (1), 73-81, 2019 | 142 | 2019 |
| Infectious complications of biological and small molecule targeted immunomodulatory therapies JS Davis, D Ferreira, E Paige, C Gedye, M Boyle Clinical microbiology reviews 33 (3), 10.1128/cmr. 00035-19, 2020 | 128 | 2020 |
| Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase AJ Kettle, CA Gedye, CC Winterbourn Biochemical pharmacology 45 (10), 2003-2010, 1993 | 109 | 1993 |
| Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial L Albiges, H Gurney, V Atduev, C Suarez, MA Climent, D Pook, ... The Lancet Oncology 24 (8), 881-891, 2023 | 93 | 2023 |
| Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase … MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ... The Lancet Oncology 25 (1), 99-107, 2024 | 85 | 2024 |
| Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial AB Lassman, SL Pugh, TJC Wang, K Aldape, HK Gan, M Preusser, ... Neuro-oncology 25 (2), 339-350, 2023 | 85 | 2023 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 83 | 2020 |
| Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity CA Gedye, A Hussain, J Paterson, A Smrke, H Saini, D Sirskyj, K Pereira, ... PloS one 9 (8), e105602, 2014 | 83 | 2014 |
| Predicting clinical outcome through molecular profiling in stage III melanoma T John, MA Black, TT Toro, D Leader, CA Gedye, ID Davis, PJ Guilford, ... Clinical Cancer Research 14 (16), 5173-5180, 2008 | 83 | 2008 |
| Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells C Gedye, J Quirk, J Browning, S Svobodová, T John, P Sluka, PR Dunbar, ... Cancer immunology, immunotherapy 58, 1635-1646, 2009 | 81 | 2009 |
| Tumor genomic testing for> 4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib) M Hussain, C Corcoran, C Sibilla, K Fizazi, F Saad, N Shore, S Sandhu, ... Clinical Cancer Research 28 (8), 1518-1530, 2022 | 76 | 2022 |
